Late-stage minority fund research profile
Avendus Future Leaders Fund is Avendus Capital's growth and pre-IPO private-equity platform, investing in scaled Indian businesses across technology, consumer, financial services and other new-economy sectors.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
Avendus Future Leaders Fund uses a late-stage minority approach across Tech, consumer, fin services.
Current evidence
Avendus Future Leaders Fund III reached a ₹850 crore first close in January 2025 and was reported in 2026 as targeting a final close of approximately ₹1,800 crore. The strategy’s 2025 investment in Parag Parikh Financial Advisory Services was a ₹140 crore secondary transaction; 2025 coverage also identifies Aragen Life Sciences as a ₹300 crore FLF investment with SBI Life. Ritesh Chandra remains Managing Partner and Head of FLF.
Strategy
Late-stage minority
Sector focus
Tech, consumer, fin services
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
Avendus Future Leaders Fund III reached a ₹850 crore first close in January 2025 and was reported in 2026 as targeting a final close of approximately ₹1,800 crore. The strategy’s 2025 investment in Parag Parikh Financial Advisory Services was a ₹140 crore secondary transaction; 2025 coverage also identifies Aragen Life Sciences as a ₹300 crore FLF investment with SBI Life. Ritesh Chandra remains Managing Partner and Head of FLF.
Investor questions
Avendus Future Leaders Fund is covered in Rupeia's private equity research universe. The current public record describes the strategy as Late-stage minority, with a sector focus of Tech, consumer, fin services. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to Avendus Future Leaders Fund in the reviewed public sources: Parag Parikh Financial Advisory Services, Aragen Life Sciences, Lenskart, Bikaji Foods, Xpressbees / Trackon, Veritas Finance, API Holdings / PharmEasy, Clear, Zoff, The Bear House, SBI General Insurance, Sagility. It does not represent a complete current portfolio unless the manager has published one.
FLF II reporting shows a ₹1,500 crore fund, ₹1,043 crore called capital and ₹940 crore invested as of September 2023, with 9 companies and 1.0x MOIC at that date. Public updates also report a ₹1,800 crore target for FLF III and a ₹140 crore PPFAS secondary investment. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: FLF II was reported at ₹1,500 crore; FLF III was reported as targeting approximately ₹1,800 crore.. Public terms or access information: Late-stage and pre-IPO minority investments in scaled businesses; the public record does not consistently disclose a standard cheque size or reserve policy.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Ritesh Chandra. Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: FLF III final close should be rechecked against the manager’s final announcement; vehicle-level net returns and complete current holdings are not publicly disclosed. Portfolio names are retained only where manager or credible transaction reporting attributes them to FLF..
2026-07-14: Avendus Future Leaders Fund III reached a ₹850 crore first close in January 2025 and was reported in 2026 as targeting a final close of approximately ₹1,800 crore. The strategy’s 2025 investment in Parag Parikh Financial Advisory Services was a ₹140 crore secondary transaction; 2025 coverage also identifies Aragen Life Sciences as a ₹300 crore FLF investment with SBI Life. Ritesh Chandra remains Managing Partner and Head of FLF.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.